beta-alanine has been researched along with latanoprost in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 7 (58.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bacharach, J; Dubiner, HB; Kopczynski, CC; Levy, B; Novack, GD | 1 |
| Kopczynski, CC; Levy, B; Lewis, RA; Novack, GD; Ramirez, N; Usner, DW | 1 |
| Robin, AL; Schehlein, EM | 1 |
| Asrani, S; Heah, T; Kopczynski, CC; Lewis, RA; Robin, AL; Serle, JB; Usner, DW | 1 |
| Radell, JE; Serle, JB | 1 |
| Kolomeyer, NN; Lee, D; Myers, JS; Razeghinejad, R; Sinha, S | 1 |
| Mehran, NA; Razeghinejad, R; Sinha, S | 1 |
| Heah, T; Kim, T; Sheng, H; Wisely, CE | 1 |
| Asrani, S; Bacharach, J; Heah, T; Holland, E; Kopczynski, CC; Lewis, RA; McKee, H; Sheng, H | 1 |
| Esfandiari, H; Tanna, AP; Teramoto, K | 1 |
| Anderson, AL; Harman, CD; Komáromy, AM; Leary, KA; Steibel, JP | 1 |
| Ahn, HS; Chang, DJ; Chang, J; Kang, HY; Lee, H; Lee, JW; Suh, JK | 1 |
4 review(s) available for beta-alanine and latanoprost
| Article | Year |
|---|---|
Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment.
Topics: Animals; Benzoates; beta-Alanine; Drug Therapy, Combination; Eye; Glaucoma; Humans; Intraocular Pressure; Isoquinolines; Latanoprost; Protein Kinase Inhibitors; rho-Associated Kinases; Signal Transduction; Sulfonamides | 2019 |
Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Drug Combinations; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Ocular Hypertension; Ophthalmic Solutions | 2020 |
New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins F, Synthetic | 2020 |
Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ocular Hypertension; Prostaglandins F, Synthetic; rho-Associated Kinases; Timolol; Treatment Outcome | 2022 |
5 trial(s) available for beta-alanine and latanoprost
| Article | Year |
|---|---|
Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Double-Blind Method; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins F, Synthetic; rho-Associated Kinases; Tonometry, Ocular; Young Adult | 2015 |
Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Corneal Pachymetry; Double-Blind Method; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins F, Synthetic; rho-Associated Kinases; Tonometry, Ocular | 2016 |
Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
Topics: Administration, Ophthalmic; Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Double-Blind Method; Drug Combinations; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; rho-Associated Kinases; Tonometry, Ocular | 2019 |
Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.
Topics: Aged; Benzoates; beta-Alanine; Double-Blind Method; Drug Combinations; Endothelium, Corneal; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Tonometry, Ocular | 2020 |
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Tonometry, Ocular; United States; United States Food and Drug Administration | 2020 |
3 other study(ies) available for beta-alanine and latanoprost
| Article | Year |
|---|---|
Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Drug Approval; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Latanoprost; Ocular Hypertension; United States; United States Food and Drug Administration | 2019 |
Reversible Corneal Endothelial Abnormalities With Netarsudil.
Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Corneal Diseases; Drug Therapy, Combination; Endothelium, Corneal; Female; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Remission Induction; Sulfonamides; Thiophenes; Timolol; Tonometry, Ocular; Withholding Treatment | 2020 |
Safety and efficacy of topically administered netarsudil-latanoprost fixed dose combination (FDC; Rocklatan™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).
Topics: Animals; Antihypertensive Agents; Benzoates; beta-Alanine; Dog Diseases; Dogs; Double-Blind Method; Glaucoma, Open-Angle; Intraocular Pressure; Latanoprost; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins F, Synthetic; Treatment Outcome | 2021 |